Risk of central lymph node metastasis in papillary thyroid carcinoma based on ultrasound ECI and serum CCL20 and IL-17A and construction of a nomogram model
Year: 2026
Type: article
Study design: Observational Study
Abstract: Objective To determine whether ultrasound elastic contrast index (ECI), serum C-C motif chemokine ligand 20 (CCL20), interleukin-17A (IL-17A) are risk factors for central lymph node metastasis in papillary thyroid cancer and to construct a nomogram for predicting CLNM in PTC. Methods This retrospective study included 308 PTC patients from Xinxiang Central Hospital (January 2022-December 2024) who underwent routine ultrasonography with postoperative pathological confirmation. Patients were randomly split 7:3 into a training set (n=216) and an internal validation set (n=92), and further classified by CLNM pathology into metastatic and non-metastatic groups. Demographic, ultrasound, and serum biomarker data were collected. Candidate predictors were screened by univariable analysis and LASSO regression with 10-fold cross-validation, followed by multivariable logistic regression to identify independent risk factors. The model’s performance was evaluated using receiver operating characteristic curve (ROC), area under the curve (AUC), calibration curve, and decision curve analysis. Bootstrap internal validation was performed to assess model stability. Results In the training set, taller-than-wide shape, multifocality, irregular margins, microcalcifications, capsular invasion, and levels of ECI, TSH, CCL20, and IL-17A were higher in the metastasis group ( P < 0.05). ECI, CCL20, and IL-17A showed positive correlations with each other and with TSH, taller-than-wide shape, multifocality, margin status, calcification, and capsular invasion ( P < 0.05). Multivariate analysis confirmed TSH, tumor size, margin, calcification, capsular invasion, ECI, CCL20, and IL-17A as independent risk factors for CLNM. ROC analysis yielded exploratory cut-off values of 3.35 for ECI, 65.21 ng/L for CCL20, and 24.61 pg/mL for IL-17A, with AUC of 0.746, 0.768, and 0.783, respectively. The nomogram showed apparent AUC of 0.960 (95% CI : 0.938-0.982) in the training set and 0.962 (95% CI : 0.929-0.994) in the internal validation set. Calibration and decision curve analysis were favorable. Bootstrap internal validation yielded an optimism-corrected AUC of 0.942; however, because variable selection was not repeated within each resample, this estimate is optimistic and true out-of-sample performance may be lower. Conclusion ECI, CCL20, IL-17A, TSH, and specific ultrasound features are risk factors for CLNM in PTC. The nomogram showed preliminary apparent performance, but external multicenter validation is required before clinical application.
Source: Frontiers in Oncology
Authors: Huiyuan Li(Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Project administration, Writing – original draft), Jianling Li(Conceptualization, Methodology, Resources, Supervision, Writing – review & editing), Ting Dong(Data curation, Formal analysis, Investigation, Visualization, Writing – original draft), Xueyun Yang(Formal analysis, Methodology, Visualization, Writing – review & editing), Yuan Li(Formal analysis, Investigation, Visualization, Writing – review & editing)
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Keywords: papillary thyroid carcinoma, central lymph node metastasis, CCL20, IL-17A, serum biomarkers, nomogram, risk prediction model, risk factors, thyroid ultrasound, thyroid-stimulating hormone, capsular invasion, microcalcifications, multifocality, tumor size, margin status, LASSO, decision curve analysis, internal validation
Open Access status: gold
Estimated APC paid: $3,801
OpenAlex ID: W7236563493
